{"answer":{"query":"xtandi","resolved_as":"name","packages":3,"applications":["NDA213674","NDA203415"],"identity":{"application_numbers":["NDA213674","NDA203415"],"marketing_categories":["NDA"],"labelers":[{"text":"ASTELLAS PHARMA US, INC.","untrusted":true}],"dosage_forms":[{"text":"CAPSULE","untrusted":true},{"text":"TABLET","untrusted":true}],"marketing_start":{"earliest":"2012-08-31","latest":"2020-08-04","packages_with_a_start_date":3}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":3,"negotiated_price_ends":null,"rows":[{"ndc":"00469012599","name":{"text":"XTANDI 40MG CAPSULE 120/BOTTLE","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00469062599","name":{"text":"XTANDI 40MG TABLETS 120/BOTTLE","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00469072560","name":{"text":"XTANDI 80MG TABLETS 60/BOTTLE","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":7004,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA213674","date":"2037-02-23","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12161628","productNo":"001"},"latest_patent_expiry":"2037-02-23","latest_exclusivity_expiry":"2026-11-17","dated_barriers":15,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":7,"exclusivities_listed":1,"fact_id":"9bb18fce2ed4dee70221d971"},{"application":"NDA203415","date":"2037-02-23","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12161628","productNo":"001"},"latest_patent_expiry":"2037-02-23","latest_exclusivity_expiry":"2026-11-17","dated_barriers":5,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":4,"exclusivities_listed":1,"fact_id":"a3851fb575615795592ffc3e"}],"label_history":{"events_total":28,"non_cmc_events":24,"counts_by_class":{"EFFICACY":13,"LABELING":11},"cmc_events":4,"recent_non_cmc_events":[{"application":"NDA203415","submission_no":26,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-07-24","documents":[{"type":"Label","date":"2026-07-27","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026lbl.pdf","untrusted":true}},{"type":"Letter","date":"2026-07-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203415Orig1s026;213674Orig1s016ltr.pdf","untrusted":true}}],"fact_id":"3a46e40208f1d5b381a5781a"},{"application":"NDA213674","submission_no":16,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-07-24","documents":[{"type":"Label","date":"2026-07-27","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026;213674s016lbl.pdf","untrusted":true}},{"type":"Letter","date":"2026-07-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203415Orig1s026;213674Orig1s016ltr.pdf","untrusted":true}}],"fact_id":"35d2535b0666538443768e51"},{"application":"NDA203415","submission_no":25,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-12-11","documents":[{"type":"Letter","date":"2025-12-12","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/203415Orig1s025,213674Orig1s015ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-12-18","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203415s025,213674s015lbl.pdf","untrusted":true}}],"fact_id":"73b2e21db2614d21219634bd"},{"application":"NDA213674","submission_no":15,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-12-11","documents":[{"type":"Letter","date":"2025-12-12","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/203415Orig1s025,213674Orig1s015ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-12-18","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203415s025,213674s015lbl.pdf","untrusted":true}}],"fact_id":"33f76f89b75d5cf76afffdb1"},{"application":"NDA203415","submission_no":24,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-03-21","documents":[{"type":"Label","date":"2025-03-24","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203415s024,213674s012lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-03-25","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/203415Orig1s024, 213674Orig1s012ltr.pdf","untrusted":true}}],"fact_id":"00c3e532c2f9ba6ae6d6cfb5"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":3,"te_code_counts":{"AB":3},"marketing_status_counts":{"Prescription":3},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA213674","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XTANDI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"80MG","untrusted":true}},{"application":"NDA213674","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XTANDI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"40MG","untrusted":true}},{"application":"NDA203415","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XTANDI","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"40MG","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":3,"most_recent":[{"recall_number":"D-0769-2018","classification":"Class II","status":"Terminated","report_date":"2018-05-16","recall_initiated":"2018-04-03","recalling_firm":{"text":"Kroger Specialty Pharmacy, Inc.","untrusted":true},"reason":{"text":"Lack of Processing Controls.","untrusted":true},"packages_named":1,"fact_id":"80a36c789cc245d31bccc7d1"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"ENZALUTAMIDE","untrusted":true},"recruiting_interventional_count":81,"not_yet_recruiting_count":16,"by_phase":{"PHASE2":28,"PHASE3":23,"PHASE1":15,"PHASE1/PHASE2":13,"NA":2},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03899155","title":{"text":"Pan Tumor Rollover Study","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Bristol-Myers Squibb","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2019-08-09","link":{"text":"https://clinicaltrials.gov/study/NCT03899155","untrusted":true}},{"nct_id":"NCT07287150","title":{"text":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2026-03-11","link":{"text":"https://clinicaltrials.gov/study/NCT07287150","untrusted":true}},{"nct_id":"NCT06136624","title":{"text":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Merck Sharp & Dohme LLC","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2023-12-31","link":{"text":"https://clinicaltrials.gov/study/NCT06136624","untrusted":true}},{"nct_id":"NCT07751133","title":{"text":"Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"University College, London","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2026-08-28","link":{"text":"https://clinicaltrials.gov/study/NCT07751133","untrusted":true}},{"nct_id":"NCT05818683","title":{"text":"A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Janssen Research & Development, LLC","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-03","start_date":"2023-04-26","link":{"text":"https://clinicaltrials.gov/study/NCT05818683","untrusted":true}}],"fact_id":"0f0e6ec03802f1ae53dd569a"}]},"spending":{"reported_under":{"generic":{"text":"Enzalutamide","untrusted":true},"brand":{"text":"Xtandi","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1968567948,"claims":167667,"beneficiaries":26490,"average_spending_per_claim_usd":11740.938575,"fact_id":"49ddfebe3f853da85c9d2e85"},{"year":2021,"gross_spending_usd":2411262129.8,"claims":198288,"beneficiaries":30007,"average_spending_per_claim_usd":12160.403705,"fact_id":"278515c15452ce1cf59f5847"},{"year":2022,"gross_spending_usd":2436795702.7,"claims":189085,"beneficiaries":27803,"average_spending_per_claim_usd":12887.303079,"fact_id":"d9f128ff79ca9f574cc2c1db"},{"year":2023,"gross_spending_usd":2601510278.2,"claims":191657,"beneficiaries":28658,"average_spending_per_claim_usd":13573.781695,"fact_id":"6391fd774636510436b4270a"},{"year":2024,"gross_spending_usd":3400769228.6,"claims":255669,"beneficiaries":35367,"average_spending_per_claim_usd":13301.453163,"fact_id":"15be44398ef5dcc3ee6612e4"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":9,"all_states_medicaid_reimbursed_usd":9530689.43,"all_states_medicaid_paid_prescriptions":744,"top_states":[{"state":"KY","medicaid_paid_prescriptions":182,"medicaid_reimbursed_usd":2459498.4,"total_reimbursed_usd":2459498.4,"packages":2,"covers":"fee_for_service_only","fact_id":"8980e914a60936ebf8803106"},{"state":"MN","medicaid_paid_prescriptions":86,"medicaid_reimbursed_usd":1064559.22,"total_reimbursed_usd":1064559.22,"packages":1,"covers":"all_record_types","fact_id":"e2169bcb3282a4338ea33233"},{"state":"WA","medicaid_paid_prescriptions":76,"medicaid_reimbursed_usd":957264.33,"total_reimbursed_usd":957264.33,"packages":1,"covers":"all_record_types","fact_id":"e14f0824ed490da141d8d2f5"},{"state":"AL","medicaid_paid_prescriptions":76,"medicaid_reimbursed_usd":934185.95,"total_reimbursed_usd":981688.62,"packages":1,"covers":"all_record_types","fact_id":"dae99eac3b140c0bcbc70cf9"},{"state":"OR","medicaid_paid_prescriptions":60,"medicaid_reimbursed_usd":889215.63,"total_reimbursed_usd":889215.63,"packages":1,"covers":"all_record_types","fact_id":"344b285b15ebbd6ca974726b"},{"state":"HI","medicaid_paid_prescriptions":62,"medicaid_reimbursed_usd":834146.4,"total_reimbursed_usd":834146.4,"packages":1,"covers":"all_record_types","fact_id":"4ebc2639f6fc25e524d83bfb"},{"state":"MA","medicaid_paid_prescriptions":61,"medicaid_reimbursed_usd":817157.66,"total_reimbursed_usd":830133.95,"packages":1,"covers":"fee_for_service_only","fact_id":"20a3514aa268e011fca3073f"},{"state":"AZ","medicaid_paid_prescriptions":72,"medicaid_reimbursed_usd":815676.94,"total_reimbursed_usd":830551.96,"packages":1,"covers":"all_record_types","fact_id":"1d67134e9bff0102f1de7a24"},{"state":"MD","medicaid_paid_prescriptions":69,"medicaid_reimbursed_usd":758984.9,"total_reimbursed_usd":759109.9,"packages":1,"covers":"fee_for_service_only","fact_id":"961d9717ca35b33a6e51ff62"}],"unlabelled_state_code_xx":null,"built_from_facts":10,"facts_fee_for_service_only":3,"older_year_facts_not_used":54,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"c6f03da5c52e556f40ff5fce","field":"ndc.listing","entity":"ndc:00469012599"},{"fact_id":"76f7ed29263b92fb935326fd","field":"ndc.listing","entity":"ndc:00469062599"},{"fact_id":"464d24bf1b5901da056ba16b","field":"ndc.listing","entity":"ndc:00469072560"},{"fact_id":"9bb18fce2ed4dee70221d971","field":"drug.generic_entry_earliest","entity":"application:NDA213674"},{"fact_id":"58fe34ec0e8030ee5ac425de","field":"drug.patent","entity":"application:NDA213674"},{"fact_id":"52cf75d43bb84483da94ea35","field":"drug.exclusivity","entity":"application:NDA213674"},{"fact_id":"a3851fb575615795592ffc3e","field":"drug.generic_entry_earliest","entity":"application:NDA203415"},{"fact_id":"587e6d4573e4df2a0daf74a5","field":"drug.patent","entity":"application:NDA203415"},{"fact_id":"7ae1c02a5d5dc67c86937149","field":"drug.exclusivity","entity":"application:NDA203415"},{"fact_id":"3a46e40208f1d5b381a5781a","field":"drug.label_event","entity":"application:NDA203415"},{"fact_id":"35d2535b0666538443768e51","field":"drug.label_event","entity":"application:NDA213674"},{"fact_id":"73b2e21db2614d21219634bd","field":"drug.label_event","entity":"application:NDA203415"},{"fact_id":"33f76f89b75d5cf76afffdb1","field":"drug.label_event","entity":"application:NDA213674"},{"fact_id":"00c3e532c2f9ba6ae6d6cfb5","field":"drug.label_event","entity":"application:NDA203415"},{"fact_id":"8626bae9ce3fa8c0accc7c77","field":"drug.te_code","entity":"application:NDA213674"},{"fact_id":"f0b912d05d6eb197289e8c09","field":"drug.marketing_status","entity":"application:NDA213674"},{"fact_id":"0d5c81e36c794c464162ec70","field":"drug.te_code","entity":"application:NDA213674"},{"fact_id":"3a418d77b79e4a1b5d0b9ece","field":"drug.marketing_status","entity":"application:NDA213674"},{"fact_id":"fe0198753f00d82e0bf34c18","field":"drug.te_code","entity":"application:NDA203415"},{"fact_id":"7623fde38afbde00b4c1932a","field":"drug.marketing_status","entity":"application:NDA203415"},{"fact_id":"80a36c789cc245d31bccc7d1","field":"ndc.recall","entity":"ndc:00469012599"},{"fact_id":"0f0e6ec03802f1ae53dd569a","field":"drug.trial_access","entity":"drug:enzalutamide"},{"fact_id":"49ddfebe3f853da85c9d2e85","field":"drug.partd_spending","entity":"drug:enzalutamide|xtandi"},{"fact_id":"278515c15452ce1cf59f5847","field":"drug.partd_spending","entity":"drug:enzalutamide|xtandi"},{"fact_id":"d9f128ff79ca9f574cc2c1db","field":"drug.partd_spending","entity":"drug:enzalutamide|xtandi"},{"fact_id":"6391fd774636510436b4270a","field":"drug.partd_spending","entity":"drug:enzalutamide|xtandi"},{"fact_id":"15be44398ef5dcc3ee6612e4","field":"drug.partd_spending","entity":"drug:enzalutamide|xtandi"},{"fact_id":"8980e914a60936ebf8803106","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469062599:KY"},{"fact_id":"e2169bcb3282a4338ea33233","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469062599:MN"},{"fact_id":"e14f0824ed490da141d8d2f5","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469062599:WA"},{"fact_id":"dae99eac3b140c0bcbc70cf9","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469062599:AL"},{"fact_id":"344b285b15ebbd6ca974726b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469012599:OR"},{"fact_id":"4ebc2639f6fc25e524d83bfb","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469062599:HI"},{"fact_id":"20a3514aa268e011fca3073f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469012599:MA"},{"fact_id":"1d67134e9bff0102f1de7a24","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469062599:AZ"},{"fact_id":"961d9717ca35b33a6e51ff62","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00469072560:MD"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}